| Species |
Human |
| Protein Construction |
TPBG/5T4(Ser32-Ser355)_x000D_
Accession # Q13641-1 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1 EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized TPBG/5T4, His & Avi, Human at 0.5 μg/ml (100 μl/Well) on the plate can bind AntiTPBG Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
38.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 50-70 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The oncofetal tumor-associated antigen 5T4 (TBGP) has been linked with CSC properties in several different malignancies. 5T4 has functional attributes that are relevant to the spread of tumors including through EMT, CXCR4/CXCL12, Wnt, and Hippo pathways which may all contribute through the mobilization of CSCs. |
| Synonyms |
M6P1; 5T4AG; WAIF1; TPBG; 5T4 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
